Keay Nakae
Stock Analyst at Chardan Capital
(4.11)
# 515
Out of 5,182 analysts
243
Total ratings
41.04%
Success rate
17.86%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Buy | $30 | $24.27 | +23.61% | 4 | Apr 22, 2026 | |
| PRQR ProQR Therapeutics | Maintains: Buy | $4 | $1.49 | +168.46% | 17 | Apr 9, 2026 | |
| IBIO iBio, Inc. | Maintains: Buy | $5 | $1.71 | +192.40% | 8 | Apr 9, 2026 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $54.02 | +85.12% | 8 | Mar 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $425 | $308.51 | +37.76% | 16 | Mar 25, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $35 | $33.71 | +3.83% | 2 | Mar 18, 2026 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $4.40 | +218.18% | 24 | Mar 16, 2026 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $4.10 | +387.80% | 14 | Mar 12, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $12 → $14 | $3.48 | +302.88% | 20 | Mar 11, 2026 | |
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $18.04 | +110.64% | 16 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $15 | $12.84 | +16.82% | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $80 | $73.60 | +8.70% | 23 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 | $0.88 | +4,427.45% | 1 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $4.28 | +16.82% | 14 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $7.82 | +347.57% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $7.32 | -18.03% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.95 | +207.69% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.39 | +1,944.99% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $15.33 | -60.86% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $1.02 | +37,154.90% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $8.03 | +584.93% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $3.56 | +180.90% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $26.74 | +227.23% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.70 | +664.71% | 3 | Feb 9, 2021 |
Alto Neuroscience
Apr 22, 2026
Maintains: Buy
Price Target: $30
Current: $24.27
Upside: +23.61%
ProQR Therapeutics
Apr 9, 2026
Maintains: Buy
Price Target: $4
Current: $1.49
Upside: +168.46%
iBio, Inc.
Apr 9, 2026
Maintains: Buy
Price Target: $5
Current: $1.71
Upside: +192.40%
Monopar Therapeutics
Mar 30, 2026
Maintains: Buy
Price Target: $100
Current: $54.02
Upside: +85.12%
Alnylam Pharmaceuticals
Mar 25, 2026
Maintains: Buy
Price Target: $425
Current: $308.51
Upside: +37.76%
Stoke Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $35
Current: $33.71
Upside: +3.83%
Coya Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $14
Current: $4.40
Upside: +218.18%
Orchestra BioMed Holdings
Mar 12, 2026
Maintains: Buy
Price Target: $20
Current: $4.10
Upside: +387.80%
SAB Biotherapeutics
Mar 11, 2026
Maintains: Buy
Price Target: $12 → $14
Current: $3.48
Upside: +302.88%
Dyne Therapeutics
Mar 9, 2026
Maintains: Buy
Price Target: $38
Current: $18.04
Upside: +110.64%
Jan 29, 2026
Upgrades: Buy
Price Target: $7 → $15
Current: $12.84
Upside: +16.82%
Jan 7, 2026
Maintains: Buy
Price Target: $60 → $80
Current: $73.60
Upside: +8.70%
Jan 5, 2026
Maintains: Buy
Price Target: $40
Current: $0.88
Upside: +4,427.45%
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.28
Upside: +16.82%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $7.82
Upside: +347.57%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $7.32
Upside: -18.03%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $1.95
Upside: +207.69%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.39
Upside: +1,944.99%
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $15.33
Upside: -60.86%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $1.02
Upside: +37,154.90%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $8.03
Upside: +584.93%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $3.56
Upside: +180.90%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $26.74
Upside: +227.23%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.70
Upside: +664.71%